Unknown

Dataset Information

0

Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids.


ABSTRACT: Natural flavonoids such as genistein, kaempferol and daidzein were previously found to be able to reduce efficiency of glycosaminoglycan synthesis in cells of patients suffering from mucopolysaccharidoses, inherited metabolic diseases with often brain disease symptoms. This feature was employed to test these compounds as potential drugs for treatment other neuronopathic lysosomal storage disorders, in which errors in sphingolipid metabolism occur. In this report, on the basis of DNA microarray analyses and quantitative real time PCR experiments, we present evidence that these compounds modify expression of genes coding for enzymes required for metabolism of sphingolipids in human dermal fibroblasts (HDFa). Expression of several genes involved in sphingolipid synthesis was impaired by tested flavonoids. Therefore, it is tempting to speculate that they may be considered as potential drugs in treatment of LSD, in which accumulation of sphingolipids, especially glycosphingolipids, occurs. Nevertheless, further studies on more advances models are required to test this hypothesis and to assess a therapeutic potential for flavonoids in this group of metabolic brain diseases.

SUBMITTER: Moskot M 

PROVIDER: S-EPMC4560762 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids.

Moskot Marta M   Jakóbkiewicz-Banecka Joanna J   Smolińska Elwira E   Banecki Bogdan B   Węgrzyn Grzegorz G   Gabig-Cimińska Magdalena M  

Metabolic brain disease 20150726 5


Natural flavonoids such as genistein, kaempferol and daidzein were previously found to be able to reduce efficiency of glycosaminoglycan synthesis in cells of patients suffering from mucopolysaccharidoses, inherited metabolic diseases with often brain disease symptoms. This feature was employed to test these compounds as potential drugs for treatment other neuronopathic lysosomal storage disorders, in which errors in sphingolipid metabolism occur. In this report, on the basis of DNA microarray a  ...[more]

Similar Datasets

| S-EPMC7359313 | biostudies-literature
| S-EPMC6952831 | biostudies-literature
| S-EPMC4536262 | biostudies-literature
| S-EPMC4043343 | biostudies-literature
| S-EPMC9089391 | biostudies-literature
| S-EPMC7264154 | biostudies-literature
| S-EPMC8198874 | biostudies-literature
| S-EPMC9204892 | biostudies-literature
| S-EPMC11309649 | biostudies-literature
| S-EPMC4369724 | biostudies-literature